Parabilis Medicines, Inc.
PBLS
Positions held
Your positionsPBLS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Parabilis Medicines, Inc. operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and treatments, attracting significant investor interest.
- The company's market capitalization stands at approximately $3.57 billion, indicating a substantial valuation in the healthcare market.
- Despite current challenges, the target mean price for PBLS is set at $41.75, suggesting potential upside from its current trading levels.
- The company's financial performance shows a negative operating margin of -3.44%, reflecting ongoing operational challenges.
- Parabilis reported a net income loss of -52.46 million in Q2 2026, continuing a trend of losses over multiple quarters.
- The stock has a strong sell signal with a score of -16.00, indicating bearish market sentiment and technical indicators pointing to further declines.
Fundamentals
| Market cap | $3.47B | Enterprise value | $2.40B | Trailing P/E | — | Forward P/E | -12.85 |
| PEG | — | Price / book | 3.31 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -343.8% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.05 |
| Current ratio | 17.91 | Free cash flow | — | Analyst recommendation | none | Mean target | $41.75 |
| 52w high | $42.49 | 52w low | $24.51 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $0.1M | $0.0M | $0.0M | $0.0M |
| Op margin | -34382.4% | — | — | — |
| Net income | -$52.5M | -$45.3M | -$34.8M | -$38.3M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$50.9M | -$47.5M | -$36.5M | -$40.2M |
Yearly (6y)
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0.0M | $0.0M |
| Op margin | — | — |
| Net income | -$146M | -$118M |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$152M | -$126M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026
2026-09-28 · Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026
2026-09-23 · MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
2026-09-01 · Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-25 · Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
2026-08-25 · Young startups miss out on biotech venture funding rebound, MassBio says
2026-08-13 · Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell
2026-08-13 · Parabilis Medicines: Q2 Earnings Snapshot
2026-08-13 · Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Price (daily)
Full chart · RSI · MACD · patterns